MENA Metabolic Conference
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

Microbial signature of aggressive form of breast cancer

, 26 August 2020/in E-News /by 3wmedia

Cancer is a result of normal cellular functions going wildly awry on a genetic level. That fact has been known for some time, but increasing evidence is showing that the human microbiome, the diverse population of microorganisms within every person, may play a key role in either setting the stage for cancer or even directly causing some forms of it. A new study from the Perelman School of Medicine at the University of Pennsylvania, led by Erle S. Robertson, PhD and James C. Alwine, PhD, has identified, for the first time, an association between two microbial signatures and triple negative breast cancer (TNBC), the most aggressive form of the disease.

‘Viruses and other microorganisms probably have much more to do with cancer, at least the propagation of cancer and promotion of it, than is really known,’ said Alwine, a professor of Cancer Biology and associate director for core services at the Abramson Cancer Center. Using a microarray technology called PathoChip containing 60,000 molecular probes to identify all known viruses and pathogenic bacteria, fungi, parasites, and other microorganisms, Robertson, a professor of Microbiology and his colleagues screened tissue samples from 100 TNBC patients.

They also examined 40 matched and non-matched controls (matched controls are non-tumour tissue from TNBC patients; non-matched controls are breast tissue from healthy patients).

The team found a distinct microbial signature distinguishing TNBC tissue from normal samples, which could be further delineated into two broad clusters, one predominantly viral and the other predominantly bacterial, with some fungi and parasites.

‘If we look at this closely, we may also find some smaller clusters within those major groups that could give us some insights to unique identifiers for individuals in these clusters,’ stated Robertson, who is also associate director for global cancer research and co-leader of the tumour virology program at the Abramson Cancer Center. He explains that the team found ‘about 30 organisms that provide a specific type of signature to give us clues for developing a diagnostic tool.’ Co-authors Sagarika Banerjee, PhD, and Kristen Peck, from the Robertson lab, screened the organisms, and Michael Feldman, MD, PhD, and Natalie Shi from the department of Pathology and Laboratory Medicine, performed the pathology examinations to identify the TNBC cases.

Among the most prevalent viruses detected were Herpesviruses, Parapoxviruses, Retroviruses, Hepadnaviruses, Polyomaviruses, and Papillomaviruses. Significant bacterial signatures included Arcanobacterium, Brevundimonas, Sphingobacteria, and Geobacillus, while fungal species Pleistophora and Piedra and parasitic organisms Foncecaea and Trichuris were among the prominent ones identified. 

Alwine emphasizes that the detection of these and the other pathogens in TNBC tissues does not necessarily mean that they actually cause cancer. ‘There are a lot of different ways to look at this,’ he pointed out. ‘It’s possible that some of the organisms we’re looking at have a causative effect, but we don’t know that. We can’t say until it’s been thoroughly tested by many more experiments.’ One possibility is that the organisms could be adding something to the cellular microenvironment that helps damaged cells to become malignant or pushes them over the edge into cancer. Alternatively, certain organisms may simply find tumor tissue a favorable environment, without having any direct involvement at all with the cancer. ‘They might just be there because it’s a good place to hang out,’ Alwine said.

In either case, finding a distinct microbial signature associated with cancer raises the prospect of new diagnostic possibilities. ‘We’re looking at the signature as a potential for being able to diagnose cancer, possibly at an earlier stage,’ Alwine explained. Penn Medicine

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:33:422021-01-08 11:10:31Microbial signature of aggressive form of breast cancer

Genetic errors may prevent heart attacks

, 26 August 2020/in E-News /by 3wmedia

Genetic errors identified in a new study led by Washington University School of Medicine in St. Louis may reduce risk of heart attacks and serve as a basis for developing new drugs designed to prevent heart disease.

To reduce risk of heart attack, the benefits of a healthy lifestyle are clear. But genetics can still stack the deck. Some people’s genes bestow a natural advantage — or disadvantage — in protecting against heart disease, the leading cause of death worldwide.

Now, a new study that included genetic data from more than 190,000 people has identified two genes that, when altered in specific ways, either promote or undermine cardiovascular health. The findings may help guide efforts to design new preventive drugs, similar to the way statins now are prescribed to lower “bad” cholesterol to reduce the risk of heart disease.

The research is from Washington University School of Medicine in St. Louis, the Broad Institute at Massachusetts Institute of Technology and Harvard.

“We identified genetic variation in several genes that associated with protection from coronary heart disease,” said first author Nathan O. Stitziel, MD, PhD, a Washington University cardiologist and assistant professor of medicine and genetics. “Our findings support the idea that therapies focused on a major pathway regulating triglycerides should help prevent the buildup of plaque in the heart’s coronary arteries and protect against heart attacks.”

To identify genes that might be relevant for drug discovery, the investigators plumbed DNA data from patients with coronary disease and from healthy controls. They searched across more than 220,000 genetic variants that altered proteins to identify those that appeared to influence heart disease risk. Errors in proteins can have major physiologic consequences.

As part of the study, the researchers confirmed past work identifying genes already shown to confer an advantage or a vulnerability in protecting against heart disease risk, and they implicated two new ones — ANGPTL4 and SVEP1. Rare errors in ANGPTL4 were associated with reduced risk of coronary artery disease. The reduction varied from 14 percent for a small error in the gene to cutting risk by about 50 percent when an entire copy of the gene was disabled. The other gene, SVEP1, showed the opposite correlation — a rare error increased risk of coronary artery disease by about 14 percent.

While ANGPTL4 has been the subject of much study, the other gene newly implicated in cardiovascular health is a bit of a mystery. In the new study, Stitziel and his colleagues showed that the error in SVEP1 also was linked to higher blood pressure in their study populations, but beyond that there are few clues to what it’s doing.

In contrast, ANGPTL4 has long been known to play a role in processing triglycerides, a type of fat that circulates in the bloodstream. Doctors measure levels of triglycerides as a marker of heart disease risk, though whether these fats play a role in causing plaque to build up in arteries historically has been a matter of debate. ANGPTL4’s role in processing triglycerides is part of a system called the lipoprotein lipase (LPL) pathway. Blocking ANGPTL4 actually opens up this pathway, allowing the body to process triglycerides from the diet and get them out of the bloodstream.

“The gene’s association with lower triglycerides has been known for a while,” said Stitziel, who also sees patients at Barnes-Jewish Hospital. “But for a long time it was not clear that high triglycerides were a cause of coronary disease rather than a marker of it. Now we know that errors in ANGPTL4 associate with both reduced triglycerides and lower risk of coronary disease. This is another piece of the puzzle that points to a causal role for triglycerides in coronary disease.” Washington University School of Medicine in St. Louis

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:33:422021-01-08 11:10:19Genetic errors may prevent heart attacks

Neurodermatitis genes influence other allergies

, 26 August 2020/in E-News /by 3wmedia

There’s a typical ‘career’ for some allergic people, and it starts very early on the skin: babies develop atopic dermatitis, food allergies may follow, then comes asthma and later on hay fever. A group of scientists led by Ingo Marenholz and Young-Ae Lee at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), working with colleagues from several institutions, has now identified seven genetic risk loci for this course of disease. Two of these loci were previously unknown and mainly influence the connection between atopic dermatitis and asthma. According to the study, the regions that determine the risk for atopic dermatitis are mainly those that also determine the risk for the further development of the typical allergic career. This course of disease is also called the ‘atopic march.’ The scientists analysed data from nearly 20,000 people.
For their meta-analysis, the researchers concentrated on cases where atopic dermatitis preceded asthma. They included 12 studies with 2,428 patients and 17,034 healthy people. All of these studies were genome-wide association studies (GWAS) based on millions of genetic variants called Single Nucleotide Polymorphisms (SNPs).

It is the first GWAS for the atopic march and showed for the first time that there are specific genetic loci influencing the march’s unfortunate course. ‘Seen from a physician’s perspective, the prominent role of atopic dermatitis genes for later-onset of asthma is very interesting,“ says Young-Ae Lee. Max Delbrück Center for Molecular Medicine

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:33:422021-01-08 11:10:26Neurodermatitis genes influence other allergies

Merck Millipore Accepts Silver Stevie® Award for AFS® E Water Purification Systems at the 2015 American Business AwardsSM

, 26 August 2020/in E-News /by 3wmedia

29 September 2015, Darmstadt, Germany — Merck Millipore, the Life Science division of Merck, accepted a Silver Stevie® Award for its AFS® E Water Purification Systems at a banquet held on Friday, September 11 in San Francisco. The award was conferred by The American Business AwardsSM, the premier business awards program in the United States.

The AFS® E systems won the silver award in the ‘Health & Pharmaceuticals – Products & Services’ category in an event dedicated to outstanding new products and technology industries. Finalists were announced in May from over 3,300 entries submitted, and Gold, Silver and Bronze winners were judged and determined by more than 200 U.S. executives. Created in 2002 to recognize the achievements of organizations and professionals worldwide, the Stevie® Awards are organized in six separate programs, including The American Business AwardsSM.

Merck Millipore was represented at the awards dinner by Mohamed Bacchus, Regional Director of Sales West – Lab Water, and Joseph Plurad, North America Field Marketing Manager – Lab Water. ‘These AFS® E water purification systems incorporate our latest innovative technologies,’ said Joseph. ‘I’m proud to accept this award on behalf of all my colleagues worldwide who helped develop and support these new systems. By listening attentively to our clinical laboratory users, we were able to take their demands — as well as unmet needs — into account. The result is impressive, with systems offering our clinical lab customers the best advanced water purification technologies, as well as a unique user interface, serviceability, and sustainability.’

The AFS® 40E, 80E, 120E and 150E Water Purification Systems provide an economical and reliable high-performance solution for clinical analyzers with daily pure water needs up to 3000 liters. These systems integrate Merck Millipore’s state-of-the-art Elix® electrodeionization module, unique E.R.A.™ technology that decreases costs by automatically optimizing water recovery based on feed water quality, as well as 24/7 real-time monitoring and remote control.
Details about The American Business AwardsSM and the list of finalists in all categories are available at: www.stevieawards.com/aba

For more information on www.merckmillipore.com/labwater

Additional Resources

> Download high resolution photo

If you would like to speak to a media relations expert, please contact: Alexandra Langlois + 33 (0)6 76 54 41 28 – alexandra.langlois@external.merckgroup.com

About Merck Millipore
Merck Millipore is the Life Science subsidiary of Merck, Darmstadt, Germany. As part of the global Life Science business of Merck, Merck Millipore offers a broad range of innovative performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the life science tools industry, the Life Science business of Merck serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the global business has around 10,000 employees, operations in 66 countries and 2014 revenues of €2.7 billion. Merck Millipore operates as EMD Millipore in the U.S. and Canada.
For more information, please visit www.merckmillipore.com

About Merck
Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
For more information, please visit http://www.merckgroup.com/en/index.html

About the Stevie® Awards
Stevie® Awards are conferred in six programs: the Asia-Pacific Stevie® Awards, the German Stevie® Awards, The American Business AwardsSM, The International Business Awards, the Stevie® Awards for Women in Business, and the Stevie® Awards for Sales & Customer Service. Stevie® Award competitions receive more than 10,000 entries each year from organizations in more than 60 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies™ recognize outstanding performances in the workplace worldwide. Learn more about the Stevie® Awards at http://www.StevieAwards.com

Merck Millipore, the M mark, AFS, and Elix are registered trademarks of, and E.R.A is a trademark of Merck KGaA, Darmstadt, Germany. Any other trademarks are the property of their respective owners.

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:33:422021-01-08 11:10:34Merck Millipore Accepts Silver Stevie® Award for AFS® E Water Purification Systems at the 2015 American Business AwardsSM

Innovative Abbott tests help in detecting tuberculosis and drug resistance

, 26 August 2020/in E-News /by 3wmedia

According to the World Health Organization, in 2014, there was an estimated 9.6 million new cases of tuberculosis (TB). TB is one of the leading, potentially-fatal infectious diseases caused by a bacterium known as Mycobacterium tuberculosis (MTB) that commonly affects the lungs. In 2014, nearly 500,000 people developed resistance to the two most powerful, anti-TB drugs known as isoniazid (INH) and rifampicin (RIF).  These drug therapies have been used for decades to treat TB, but resistance is becoming widespread from inappropriate or incorrect use. Today, molecular tests from Abbott are available to help doctors diagnose tuberculosis and to detect resistance to INH and RIF. The first test, Abbott’s Realtime MTB (CE-marked), is designed to qualitatively detect MTB in samples from individuals suspected of having tuberculosis. The second test, the RealTime MTB RIF/INH Resistance, was recently CE-marked and is designed to identify single resistance to INH or RIF as well as resistance to both drugs. At this year’s 46th Union World Conference on Lung Health (Cape Town, South Africa), Abbott hosted a satellite symposium titled “Advancing to the Next Level of Molecular Testing for Mycobacterium Tuberculosis (MTB)”.

www.abbottmolecular.com
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:33:422021-01-08 11:10:21Innovative Abbott tests help in detecting tuberculosis and drug resistance

Genetics can increase the risk of heart disease in women

, 26 August 2020/in E-News /by 3wmedia

The researchers from University College London studied a group of genes that have previously been linked to an increased risk of disease in the arteries. They studied data from nearly 4,000 men and women from across Europe, comparing their genes, their artery thickness and their artery health.

The scientists, led by BHF Professor Steve Humphries, believe they have pinpointed the gene in the group that is associated with an increased risk of a heart attack or stroke in women, but not in men.

Called BCAR1, the gene they identified is involved in many processes in the body that are affected by the female sex hormone oestrogen. The researchers believe that a high risk version of the BCAR1 gene – the GG version – when combined with a woman’s naturally occurring high oestrogen levels, could lead to the increased risk of cardiovascular disease compared with the low risk version – the AA version. Men with the GG version of the BCAR1 gene do not seem to be affected.

Over the five-year study, women with the high risk BCAR1 gene – around a third of those studied – had an increased risk (6.1%) of having a heart attack, stroke or diseased blood vessels compared with those with the low risk version of the gene (2.5%).

Heart disease is the major cause of heart attack and someone has a heart attack in the UK every three minutes. Understanding what puts people at risk of heart attacks is an important part of finding ways to prevent them and potentially treat people with medication to lower their risk of having a heart attack. British Heart Foundation

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:33:422021-01-08 11:10:29Genetics can increase the risk of heart disease in women

Tumour suppressor genes curb growth in neighbouring cells

, 26 August 2020/in E-News /by 3wmedia

Researchers at IRB Barcelona unravel a role for tumour suppressor genes in restricting the growth of neighbouring cell populations.

The study might have implications for understanding the early events of tumorigenesis and the selection of the tumour-initiating cells.
The healthy development of an organism depends on its tissues and organs growing to the right size, stopping when they need to, and maintaining stability in their form and function. Correct development depends on the availability of nutrients to the cells in their environment, a process that is tightly controlled by signalling mechanisms that occur within and between the cells that form these structures. Disruptions in this signalling can lead to unbalanced growth within a tissue or organ, and can give rise to conditions such as cancer.

The TOR and PI3K signalling pathways regulate tissue growth according to nutrient availability, and are frequently over-activated in human cancer. In the study published, Institute for Research in Biomedicine (IRB Barcelona) PhD student Ana Ferreira and Group Leader and ICREA Research Professor Marco Milán report that the over-activation of these two pathways not only causes the excess growth of cells and tissues, but also restrict the growth of neighbouring cell populations.

They present evidence that the proteoglycan Dally, a protein that is known to modulate the spreading, stability and activity of the growth-promoting signalling molecule called Dpp (in flies) or TGF-β (in humans), is regulated by these two pathways and mediates the effects on neighbouring populations. “They do so by competing for Dpp”, says Ana Ferreira, first author of the paper and funded by a PhD fellowship from Portugal’s Fundação para a Ciência e a Tecnologia.

‘PTEN, a gene that negatively regulates the PI3K pathway, is one of the most commonly lost tumour suppressors in human cancer. Understanding whether this pathway also affects TGF-β spreading in mammals may help us to gain insight into the early events of tumorigenesis and the selection of the tumour-initiating cells,’ she confirms.

‘Tumour initiating cells might be selected by their ability to compete for limiting growth factors and their capacity to restrict the growth of neighbouring cell populations,’ says Marco Milán, head of the Development and Growth Control Laboratory at IRB Barcelona. ‘Seventy percent of men with prostate cancer are estimated to have lost a copy of the PTEN gene at the time of diagnosis. It will be interesting to determine whether this mechanism, identified in fruit flies, is also active in humans.’ IRB Barcelona

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:33:422021-01-08 11:10:40Tumour suppressor genes curb growth in neighbouring cells

New cytoplasmic role for proteins linked to neurological diseases, cancers

, 26 August 2020/in E-News /by 3wmedia

Researchers at UT Southwestern Medical Center have identified a second role for a class of RNA-binding proteins, revealing new insights about neurological diseases and conditions associated with this protein such as autism, epilepsy, and certain types of cancer.

“These data should promote a re-evaluation of those diseases to see if this new function that we’ve identified contributes to those defects,” said senior study author Dr. Michael Buszczak, Associate Professor of Molecular Biology and with the Hamon Center for Regenerative Science and Medicine at UT Southwestern.

The study indicates that RNA-binding fox (Rbfox) proteins oversee translation of messenger RNA, or mRNA, into proteins. Using the fruit fly Drosophila as a model, researchers showed that the Rbfox1 protein, in particular, has this regulatory role.

Rbfox1 proteins were known to play a key role in splicing together coding portions of genes called exons to form mRNA, which is subsequently translated to form proteins. Splicing largely takes place within the nucleus of cells, where many Rbfox1 proteins are found. But there are also variants of Rbfox1 proteins found in the cytoplasm – the portion of the cell outside the nucleus – and the function of those cytoplasmic proteins had not been understood. 

“We found that cytoplasmic Rbfox1 represses the production of specific proteins,” Dr. Buszczak said.

The lead author of the study, UT Southwestern Molecular Biology graduate student Arnaldo Carreira-Rosario, found that Rbfox1 binds to specific elements at the ends of mRNA molecules, preventing these mRNAs from being translated into proteins. If Rbfox1 proteins are lost and mRNA is no longer repressed, that could lead to aberrant growth of cells, or cancers.

The researchers found that cytoplasmic forms of Rbfox1 were required for germ cell development in Drosophila. “Without this protein, the germ cells are blocked in a very specific stage of differentiation and just linger there. They can’t differentiate into mature eggs,” said Dr. Buszczak, an E.E. and Greer Garson Fogelson Scholar in Medical Research.

This block leads to sterility in female Drosophila and, in other contexts, can result in an inappropriate proliferation of cells, which underlies cancer.

Work by co-author Dr. Mani Ramaswami of Trinity College Dublin in Ireland points to a link between the newly identified function of Rbfox1 proteins and neuronal development and function, which could have important implications for a number of the neuronal disorders linked to disruption of Rbfox1.

“The idea is that loss of Rbfox1 causes disease by disrupting protein expression, not RNA splicing,” Dr. Buszczak said. “If this interpretation is correct, then it has implications for how one would develop therapeutics to treat the disease in question.” UT Southwestern Medical Center

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:33:422021-01-08 11:10:17New cytoplasmic role for proteins linked to neurological diseases, cancers

New test may improve diagnosis and treatment of pancreatobiliary and other gastrointestinal cancers

, 26 August 2020/in E-News /by 3wmedia

By collecting samples from the portal vein — which carries blood from the gastrointestinal tract, including from the pancreas, to the liver — physicians can learn far more about a patient’s pancreatic cancer than by relying on peripheral blood from a more easily accessed vein in the arm.

Primary tumours shed cancerous cells, known as circulating tumour cells (CTCs), into the blood. These have been widely studied as prognostic biomarkers for various cancers. Because these cells are often larger, irregularly shaped and tend to cluster together, they get trapped in smaller vessels.

The authors hypothesized that most cells released from a gastrointestinal tumour would flow into the portal vein and then get sequestered by the narrow vessels in the liver. These cells would not reach the peripheral venous system. CTCs from gastrointestinal tumours are rarely identified in the peripheral blood until the cancer is widely metastatic.

To test this theory, researchers from the University of Chicago used an ultrasound-guided endoscope and a small needle to take blood from the portal vein during routine diagnostic endoscopies. They found CTCs in 100 percent of 18 patients with suspected tumours in the pancreas and bile ducts. Tests using peripheral blood samples, the standard method, detected tumours cells in only 4 of the 18 patients.

To test this theory, researchers from the University of Chicago used an ultrasound-guided endoscope and a small needle to take blood from the portal vein during routine diagnostic endoscopies. They found CTCs in 100 percent of 18 patients with suspected tumors in the pancreas and bile ducts. Tests using peripheral blood samples, the standard method, detected tumors cells in only 4 of the 18 patients.
‘We demonstrated that this method is potentially quite valuable as well as non-invasive, feasible and safe,’ said study director Irving Waxman, MD, professor of medicine and surgery and director of the Center for Endoscopic Research and Therapeutics at the University. ‘We had no complications related to portal vein blood acquisition.’ University of Chicago

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:33:422021-01-08 11:10:24New test may improve diagnosis and treatment of pancreatobiliary and other gastrointestinal cancers

Population-based screening study of asymptomatic persons to start in China using GastroPanel biomarkers to identify gastric cancer risk

, 26 August 2020/in E-News /by 3wmedia

A gastric cancer risk screening study will be organized in Chinese healthcare centres by the China Health Promotion Foundation. The foundation is a public organization, managed by the Chinese Ministry of Health.
The multi-centre study will be conducted by fifty to one hundred primary healthcare units. The screening of about half a million 40-80-year-old asymptomatic persons will be tested with GastroPanel biomarkers, delivered by Biohit Oyj. The parties have agreed not to disclose the value of the contract. Data collection and analysis, including evaluation, are planned to be finalized at the end of 2016. The sample collection has started in the summer of 2015.
GastroPanel is a non-invasive blood test for stomach health. The test diagnoses Helicobacter pylori infection and atrophic gastritis, caused by H. pylori infection or autoimmune disease. These results can be used to assess whether asymptomatic patients have an increased risk of gastric or esophageal cancer, peptic ulcer disease or risk of vitamin B12-, calcium-, magnesium- and iron malabsorption and if further examinations or treatments are needed.
According to CEO Liu Feng, Biohit Biotech (Hefei) Co., Ltd, ’The most important risk factors for stomach cancer are H. pylori infection and atrophic gastritis, which often are asymptomatic, and can be accurately detected by GastroPanel biomarkers used for this population-based screening. Early detection of risk groups is important for the effective prevention of gastric cancer.’
CEO Semi Korpela, Biohit Oyj said: ‘This is an outstanding opening for GastroPanel biomarkers in the screening of asymptomatic subjects to identify the risk groups for gastric cancer and vitamin B12 malabsorption among other things. Gastric cancer is the leading cause of cancer related mortality in China. The use of the very informative GastroPanel for the screening of gastric cancer risk offers the possibility of prevention and early detection of stomach cancers. Based on correct diagnosis, screening reduces sick leaves and loss of labour input, as well as self-medication with its associated risks. Early detection of risk conditions for gastric cancer and vitamin and mineral deficiencies saves healthcare costs and human suffering as well.’

www.biohithealthcare.cominvestor.relations@biohit.fi
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:33:422021-01-08 11:10:32Population-based screening study of asymptomatic persons to start in China using GastroPanel biomarkers to identify gastric cancer risk
Page 166 of 231«‹164165166167168›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

March 2026

CLi Cover MRCH 2026
11 March 2026

Isomorphic Labs unveils IsoDDE, a unified AI drug design engine surpassing AlphaFold 3 in biomolecular prediction

11 March 2026

Androgen testing for PCOS diagnosis

9 March 2026

DiaSys Diagnostic Systems | ACE FS

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription